Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.79 |
| ▸ | CNR2 | P34972 | 1/20 | 0.79 |
| ▸ | THRB | P10828 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CASP1 | P29466 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | HPGD | P15428 | 3/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17694537 | 0.92 | CNR1 (0.67) | CNR1CNR2KDM4EALDH1A1HPGD | |
| SCHEMBL844571 | 0.88 | CNR1 (0.79) | CNR1CNR2THRBKDM4EADORA1 | |
| Sad448 SCHEMBL844484 | 0.88 | CNR1 (1.00) | CNR1CNR2THRBKDM4EADORA1 | |
| SCHEMBL844174 | 0.87 | CNR1 (0.87) | CNR1CNR2THRBKDM4EADORA1 | |
| Hydrochloric Acid SCHEMBL844735 | 0.86 | CNR1 (0.86) | CNR1CNR2THRBKDM4EADORA1 | |
| SCHEMBL17694543 | 0.86 | CNR1 (0.60) | CNR1CNR2KMT2AMEN1 | |
| SCHEMBL844485 | 0.86 | CNR1 (0.75) | CNR1CNR2THRBKDM4EADORA1 | |
| SCHEMBL17692331 | 0.86 | CNR1 (0.90) | CNR1CNR2THRBKDM4EADORA1 | |
| SCHEMBL844516 | 0.85 | CNR1 (0.75) | CNR1CNR2THRBKDM4ETSHR | |
| SCHEMBL844904 | 0.84 | CNR1 (0.72) | CNR1CNR2THRBKDM4EADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10016441-B2 | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension | NOVARTIS AG (CH) | 2018-07-10 | — | — | US | disclosed |
| US-20170239268-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | ALCON INC. (CH) | 2017-08-24 | — | — | US | disclosed |
| US-9604949-B2 | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension | NOVARTIS AG (CH) | 2017-03-28 | — | — | US | disclosed |
| US-20160108012-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | NOVARTIS AG (CH) | 2016-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160108012-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | PTGIR, PTGIS, PTGS1 | CNR1 952/4885CNR2 462/4885THRB 2729/4885 |
| US-10016441-B2 | Prostaglandin conjugates and derivatives for treating glaucoma and ocular hypertension | PTGIR, PTGIS, PTGS1 | CNR1 952/4885CNR2 462/4885THRB 2729/4885 |
| US-20170239268-A1 | PROSTAGLANDIN CONJUGATES AND DERIVATIVES FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION | PTGIR, PTGIS, PTGS1 | CNR1 952/4885CNR2 462/4885THRB 2729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.